SCT 650C
Alternative Names: Recombinant anti-IL-17A antibody; SCT-650CLatest Information Update: 12 Jan 2024
At a glance
- Originator Sinocelltech
- Class Monoclonal antibodies
- Mechanism of Action Interleukin 17 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 12 Jan 2024 Sinocelltech plans a phase II in Axial spondyloarthritis in Turkey (SC) (NCT06197009)
- 14 Jun 2023 Sinocelltech has patents pending for humanized anti-IL17a antibody and use thereof, worldwide
- 14 Jun 2023 Sinocelltech has patent protection for humanized anti-IL17a antibody and use thereof in Japan